相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC).
A. J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
Aung Naing et al.
CLINICAL CANCER RESEARCH (2012)
Serum Cholesterol and mTOR Inhibitors: Surrogate Biomarker or Epiphenomenon?
Daniel C. Cho et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
Michael A. Davies et al.
CLINICAL CANCER RESEARCH (2012)
Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus
Chee Khoon Lee et al.
CLINICAL CANCER RESEARCH (2012)
Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
Victor Moreno Garcia et al.
CLINICAL CANCER RESEARCH (2012)
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis
Cristina Gomez-Fernandez et al.
EUROPEAN JOURNAL OF CANCER (2012)
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Tim Eisen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Paronychia and Pyogenic Granuloma Induced by New Anticancer mTOR Inhibitors
Vincent Sibaud et al.
ACTA DERMATO-VENEREOLOGICA (2011)
Therapy With m-TOR Inhibitors Decreases the Response to the Pandemic Influenza A H1N1 Vaccine in Solid Organ Transplant Recipients
E. Cordero et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Temsirolimus in VEGF-refractory metastatic renal cell carcinoma
M. J. MacKenzie et al.
ANNALS OF ONCOLOGY (2011)
Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction
Sachin Gupta et al.
ANTI-CANCER DRUGS (2011)
Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
Y. Wang et al.
BRITISH JOURNAL OF CANCER (2011)
Novel Feedback Inhibition of Surface Antigen Synthesis by Mammalian Target of Rapamycin (mTOR) Signal and Its Implication for Hepatitis B Virus Tumorigenesis and Therapy
Chiao-Fang Teng et al.
HEPATOLOGY (2011)
Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus
Jose Pablo Maroto et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors
Sheri L. Spunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
Sylvie Negrier et al.
LANCET ONCOLOGY (2011)
Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
Thomas E. Hutson
ONCOLOGIST (2011)
Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow
Ana M. Molina et al.
ONCOLOGIST (2011)
The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile
Beatrice T. Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
S. Yang et al.
BRITISH JOURNAL OF CANCER (2010)
Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks
Jann N. Sarkaria et al.
CLINICAL CANCER RESEARCH (2010)
The role of mTOR in memory CD8+T-cell differentiation
Koichi Araki et al.
IMMUNOLOGICAL REVIEWS (2010)
A Phase 1 Clinical Study of Temsirolimus (CCI-779) in Japanese Patients with Advanced Solid Tumors
Yasuhito Fujisaka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
A Versatile Role of Mammalian Target of Rapamycin in Human Dendritic Cell Function and Differentiation
Michael Haidinger et al.
JOURNAL OF IMMUNOLOGY (2010)
Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling
Rupal S. Bhatt et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
Holger Gerullis et al.
MEDICAL ONCOLOGY (2010)
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Virginia E. Kwitkowski et al.
ONCOLOGIST (2010)
Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy
Michael M. Vickers et al.
UROLOGY (2010)
Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus
Julien Hadoux et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2010)
Metastatic renal cell cancer treatments: An indirect comparison meta-analysis
Edward J. Mills et al.
BMC CANCER (2009)
Analysis of PTEN and HIF-1α and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-α
Robert A. Figlin et al.
CANCER (2009)
Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
Premal H. Patel et al.
CLINICAL GENITOURINARY CANCER (2009)
Comparison of Temsirolimus Pharmacokinetics in Patients With Renal Cell Carcinoma Not Receiving Dialysis and Those Receiving Hemodialysis: A Case Series
Gianluigi Lunardi et al.
CLINICAL THERAPEUTICS (2009)
An Emerging Role of mTOR in Lipid Biosynthesis
Mathieu Laplante et al.
CURRENT BIOLOGY (2009)
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
Maurizio Zangari et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
Janice P. Dutcher et al.
MEDICAL ONCOLOGY (2009)
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2008)
Rapamycin down-regulates LDL-receptor expression independently of SREBP-2
Laura J. Sharpe et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
J. P. Boni et al.
BRITISH JOURNAL OF CANCER (2008)
MTORCI inhibitors: is temsirolimus in renal cancer telling us how they really work?
C. Le Tourneau et al.
BRITISH JOURNAL OF CANCER (2008)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
Alfredo Toschi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: A trial of the eastern cooperative oncology group (E1500)
Kishan J. Pandya et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management - The renal insufficiency and anticancer medications (IRMA) study
Vincent Launay-Vacher et al.
CANCER (2007)
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
In vitro metabolic study of temsirolimus: Preparation, isolation, and identification of the metabolites
Ping Cai et al.
DRUG METABOLISM AND DISPOSITION (2007)
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
Daniel Cho et al.
CLINICAL GENITOURINARY CANCER (2007)
Prognostic relevance of the mTOR pathway in renal cell carcinoma - Implications for molecular patient selection for targeted therapy
Allan J. Pantuck et al.
CANCER (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Targeting von Hippel-Lindau pathway in renal cell carcinoma
Premal H. Patel et al.
CLINICAL CANCER RESEARCH (2006)
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer
Manuel Hidalgo et al.
CLINICAL CANCER RESEARCH (2006)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
I. Duran et al.
EUROPEAN JOURNAL OF CANCER (2006)
Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
Donatella Del Bufalo et al.
CANCER RESEARCH (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
Therapeutic targets - MTOR and related pathways
Janet E. Dancey
CANCER BIOLOGY & THERAPY (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma
TM Mekhail et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
E Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
CJA Punt et al.
ANNALS OF ONCOLOGY (2003)
Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience
E Morelon et al.
TRANSPLANTATION PROCEEDINGS (2003)
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
E Morelon et al.
TRANSPLANTATION (2001)
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
M Hidalgo et al.
ONCOGENE (2000)
TOR, a central controller of cell growth
T Schmelzle et al.
CELL (2000)
分享论文
